Impact Biomedical Inc.

IBO NYSE SEC CIK 1834105
Follow Impact Biomedical Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $21K +16.7% vs same quarter last year
Net income −$645K +56.1% vs same quarter last year
EPS, diluted −$0.08 +94.7% vs same quarter last year
Operating cash flow $11K +101.8% vs same quarter last year
Revenue by quarter
$7K
$18K
$7K
$7K
$3K
$21K
Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$30M−$20M−$10M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$11.8M
FY24−$24.7M
FY23−$4.3M
FY22−$7.3M
FY21-